Ilgaper

Repaglinide, the active ingredient in Ilgaper, is a Meglitinide presented as a tablet for oral use. It is used to improve blood glucose control in adults with type 2 diabetes mellitus, typically as an adjunct to diet and exercise. The drug acts by stimulating rapid insulin release from pancreatic beta‑cells, providing a short‑acting glucose‑lowering effect that is especially useful for post‑prandial glucose excursions.

GNH USA supplies Ilgaper as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide across the globe.

Repaglinide is indicated for the management of type 2 diabetes mellitus, targeting post‑prandial hyperglycemia. - Type 2 diabetes mellitus: improves overall glycemic control when combined with diet and exercise. - Post‑prandial hyperglycemia: reduces glucose spikes after meals. - Adjunct therapy: used when other oral agents do not achieve target HbA1c.

Repaglinide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Hypoglycemia: low blood sugar episodes, especially if meals are missed. - Nausea: mild stomach upset. - Headache: transient cranial discomfort. - Dizziness: light‑headed feeling. - Diarrhea: loose stools. - Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects: - Severe hypoglycemia: prolonged low glucose requiring assistance. - Allergic reactions: rash, itching, or swelling. - Hepatotoxicity: abnormal liver enzyme elevations. - Pancreatitis: abdominal pain with elevated enzymes.

When prescribing Repaglinide, clinicians should consider several precautionary measures to ensure safe use. - Monitor blood glucose: adjust dose based on fasting and post‑prandial readings. - Renal impairment: use lower doses or avoid in severe dysfunction. - Hepatic impairment: consider dose reduction in moderate liver disease. - Concomitant sulfonylureas: avoid combined use to reduce hypoglycemia risk. - Elderly patients: start with the lowest effective dose and monitor closely. - Store at ambient temperature: keep tablets in original container, protect from moisture and light.

Repaglinide interacts with several medicines that can alter its glucose‑lowering effect or increase toxicity.

Major Interactions (Avoid): - Strong CYP2C8 inhibitors (e.g., gemfibrozil): may cause dangerous hypoglycemia. - Insulin or other sulfonylureas: additive risk of severe hypoglycemia. - MAO‑B inhibitors (e.g., selegiline): can enhance hypoglycemic effect.

Moderate Interactions (Monitor Closely): - CYP2C8 inducers (e.g., rifampicin): may reduce Repaglinide efficacy. - Beta‑blockers: may mask hypoglycemia symptoms. - NSAIDs (e.g., ibuprofen): can potentiate hypoglycemia in some patients.